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Abstract
Background: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor
locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this
diagnostic approach. We analyzed the potential impact of FDG-PET/CT in stage definition and target volume
delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
Methods: Twenty seven patients with biopsy proven anal carcinoma were enrolled. Pathology was squamous cell
carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2. Simulation
was performed by PET/CT imaging with patient in treatment position. Gross Tumor Volume (GTV) and Clinical
Target Volume (CTV) were drawn on CT and on PET/CT fused images. PET-GTV and PET-CTV were respectively
compared to CT-GTV and CT-CTV by Wilcoxon rank test for paired data.
Results: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from
M0 to M1 leading to change the treatment intent from curative to palliative in a case.
Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
PET-GTV and PET-CTV resulted significantly smaller than CT-GTV (p = 1.2 × 10
-4) and CT-CTV (p = 2.9 × 10
-4). PET/
CT-GTV and PET/CT-CTV, that were used for clinical purposes, were significantly greater than CT-GTV (p = 6 × 10
-5)
and CT-CTV (p = 6 × 10
-5).
Conclusions: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the
carcinoma of the anal canal. Clinical stage variation occurred in 18.5% of cases with change of treatment intent in
3.7%. The GTV and the CTV changed in shape and in size based on PET/CT imaging.
Background
Carcinoma of the anal canal has shown an increasing
incidence over the last decades accounting for approxi-
mately 0.5-1 new case per year every 100,000 inhabitants
in Western countries [1,2]. The treatment approach
moved from an extensive surgical approach consisting
of abdominal-perineal resection to a conservative
chemo-radiation regimen proposed firstly by Nigro et al.
who reported high response and survival rates after a
combination of radiotherapy and chemotherapy [3]. The
efficacy of such an approach was confirmed by phase III
trials [4,5]. Multivariate analysis showed that the two
most significant prognostic factors are tumor size and
nodal status related to the TNM stage [6]. Conse-
quently, the efficacy of treatment relies on accurate sta-
ging of the primary tumor and the regional lymph
nodes [7]. Moreover, the precise identification of the
radiotherapy treatment volume plays a crucial role in
order to avoid geographic miss and appropriately boost
nodal disease [8].
(18)F-fluorodeoxyglucose positron emission tomogra-
phy fused with computed tomography (FDG-PET/CT)
imaging has an emerging role in staging and treatment
planning of various tumor locations and a number of lit-
erature studies show that also the carcinoma of the anal
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[6,9-13].
The present prospective study aims to analyze the
potential impact of FDG-PET/CT in staging and target
volume delineation of patients affected by carcinoma of
the anal canal and candidates for curative radiotherapy
combined with concomitant chemotherapy.
Methods
Patients
From January 2005 to May 2008, 27 patients, 9 males
and 18 females, aged from 36 to 90 years (mean and
median 66 years), performance status of 80-100 (med-
ian 90) according to Karnofsky scale with biopsy pro-
ven anal carcinoma, were enrolled in the present study
after obtaining informed consent following the rules of
our institution. Pathology was squamous cell carci-
noma in 20 cases, cloacogenic carcinoma in 3, adeno-
carcinoma in 2, and basal cell carcinoma in 2. Tumor
was confined in the anal canal in 10 cases, extended to
the lower rectum in 3 cases, to the anal margin in 8
cases and to both these areas in 6 cases. Baseline
work-up included physical examination, blood count,
renal and liver function tests, endoscopy, CT-scan with
contrast of the upper and lower abdomen, and chest
X-rays. One patient was HIV positive. The main
patient characteristics are reported in Table 1. All
cases were discussed in a multidisciplinary conference
with surgeons, radiation oncologists, and medical
oncologists.
PET/CT simulation
Simulation was performed by PET/CT hybrid scanner
(Biograph 16 HI-REZ, Siemens, Hoffman Estates, IL)
with patient in supine position with knee-ankle
positioning device to improve the reproducibility at each
treatment session. The CT scanner was used both for
attenuation correction of PET data and for localization
of FDG uptake in PET images. All patients were advised
to fast for at least 8 hours prior to PET/CT examina-
tion. After injection of 5.18 MBq of FDG per kg of body
weight, patients were rested for a period of about 60
minutes in a comfortable chair. Emission images ranging
from the proximal femur to the base of the skull were
acquired for 3-4 minutes per bed position. Field of view
was of 50 cm with a matrix of 512 × 512 pixels for CT
and of 128 × 128 for PET. The processed images were
displayed in coronal, transverse, and sagittal plans. After
image acquisition, PET/CT data sets were sent to the
treatment planning system Pinnacle (Philips, ADAC
Laboratories, Milpitas, CA) through local network.
Target volume delineation
Treatment volumes including GTV, CTV, and organs at
risk (bladder and femoral heads) were drawn on CT and
then on PET/CT fused images by the same radiation
oncologist with a specific experience in the treatment of
gastro-intestinal tract tumors. In particular, the GTV
was drawn manually on CT and semi-automatically on
PET images. For delineating the PET/CT-GTV and the
PET/CT-CTV, the operator considered both CT and
PET information outlining the volume identified by one
or by both imaging modalities. The CTV was drawn
manually on CT and on PET/CT images taking into
account respectively the CT-GTV and PET/CT-GTV
contours. The GTV included the primary tumor exten-
sion and the involved lymph nodes. The CTV sur-
rounded the GTV with margins of at least 1.5 cm at the
level of the primary tumor and included the uninvolved
regional lymph nodal areas, i.e. bilateral inguinal, exter-
nal and internal iliac, perirectal, and presacral lymph
nodes (Figure 1).
Lymph nodes were considered positive at CT-scan
when greater than 15 mm in diameter or when contain-
ing areas of necrosis. A focus was considered positive at
PET when the activity was significantly above the
expected background and could not be explained by a
normal structure. For delineation on PET/CT images, a
fixed threshold value of 40% of the maximum uptake in
the lesion (whichever primary tumor, liver metastasis or
lymph node) was chosen as described in a previous arti-
cle on the use of PET/CT in rectal cancer [14]. For
treatment purposes, PTV was obtained by 10 mm sym-
metric expansion of CTV taking into account setup
uncertainties and organ motion. The GTV with sym-
metric expansion of 10 mm was used as a volume for
boosting macroscopic disease.
A 3-dimension conformal treatment plan was per-
formed to a total dose of 54.0-65.0 Gy (median 59.4
Table 1 Main patient characteristics.
Total number 27
Gender 18 females
9 males
Median age 66 (range 36-90)
Median Karnofsky performance status 90 (range 80-100)
Clinical stage
(baseline work-up with CT alone)
2T 1N 0M 0
4T 2N 0M 0
9T 3N 0M 0
2T 1N 1M 0
4T 2N 2M 0
2T 3N 2M 0
1T 4N 2M 0
1T 3N 3M 0
1T 4N 3M 0
1T 3N 2M 1
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Page 2 of 7Gy) to the macroscopic disease and to 45.0 Gy to the
potentially microscopically invaded regions with con-
ventional daily fractionation of 1.8-2.0 Gy by using 6-
15 MV photons for curative treatments. The case trea-
ted with palliative intent was irradiated to a total dose
of 35.0 Gy with daily fractionation of 2.5 Gy. Concomi-
tant chemotherapy was given by cisplatin and 5-fluor-
ouracil in 15 cases and mytomicin and 5-fluorouracil
in 8 cases.
Statistical analysis
PET-GTV and PET-CTV were respectively compared to
CT-GTV and CT-CTV by Wilcoxon rank test for paired
data. A P-value < 0.05 was considered to be statistically
significant. Data were reported as mean ± standard
deviation and 95% confidence interval (CI) or as experi-
mental percentage with 95% CI, calculated using the
binomial distribution.
The following additional volumes were considered for
the mismatch analysis:
- the volume identified by PET but not by CT
(PEToutCT),
- the volume identified by CT but not by PET
(CToutPET),
- the common volume of CT and PET (CT&PET).
Results
The average tumor-to-background ratio in the examined
lesions was 22.0 ± 10.5. Using a 40% fixed isoactivity
level of the signal maximum of the tumor, liver lesion
or suspicious node, the resulting activity level was
always above the background activity.
PET images showed extensive FDG tumor uptake in
all but one case of squamous cell carcinoma T3N0 M0
in which the accumulation of the radiotracer was limited
to a small portion of the tumor mass detectable by clini-
cal examination and CT. PET/CT fused images led to
change the stage in 5/27 cases (18.5%; CI: 6.2% - 37.0%).
Three of these changes were related to the lymph node
stage that changed from N0 to N2 (Figure 2) and two to
the detection of liver lesions showing FDG uptake at
PET (Table 2). In the three cases presenting with FDG
uptake in inguinal nodes, a fine-needle ago-biopsy
(FNAB) confirmed the presence of tumor cells. The
Figure 1 PET/CT image in axial view of a T3N2 case. Different colours are used to highlight the contours of the treatment volumes: CT-GTV
(blue), PET-GTV (red), PET/CT-GTV (purple), CT-CTV (light blue), and PET/CT-CTV (yellow). The PET/CT GTV and the PET/CT-CTV were used for
treatment purposes.
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Page 3 of 7detection of liver lesions was confirmed by contrast CT
and MRI scans. The case with multiple lesions in the
liver was treated with palliative radiotherapy followed by
chemotherapy whereas the other case presenting with a
single FDG uptake lesion received combined radio-che-
motherapy as the other cases treated by curative intent.
After radio-chemotherapy, this patients underwent sur-
gical resection of the remaining liver lesion that con-
firmed the finding of metastasis.
PET/CT led to change GTV and CTV contours in 15/
27 (55.6%; CI: 34.8 - 74.3) and in 10/27 cases (37.0%;
CI: 19.0 - 57.6) cases respectively. In particular, changes
in GTV contours occurred in 12/15 (80%; CI: 53.0 -
95.7) cases staged T3-T4 and in 3/12 (25%; CI: 5.5 -
56.1) cases staged T1-T2. As far as the volume size, the
analysis by Wilcoxon rank test showed PET-GTV and
PET-CTV to be significantly smaller than CT-GTV (p =
1.2 × 10
-4) and CT-CTV (p = 2.9 × 10
-4) respectively.
PET/CT-GTV and PET/CT-CTV, that were used for
clinical purposes, were significantly greater than CT-
GTV (p = 6 × 10
-5)a n dC T - C T V( p=6×1 0
-5). The
mean difference GTV (9.2 ± 12.8 cc; 95% CI: 4.2 - 14.3
cc) amounted to an average 11.1% of the CT-GTV
volume. This difference was in proportion higher than
the corresponding mean difference between PET/CT-
CTV and CT-CTV (50.3 ± 26.6 cc; 95% CI: 39.7 - 60.8
cc) which amounted, on average, to 5.1% of the CT-
CTV volume. The analyzed volumes for all patients are
reported in Table 3. The mean and range values of the
additional volumes analyzed to compare PET/CT and
Figure 2 (a – b) CT (a) and PET/CT (b) in axial view showing a lymph node of about 1 cm in diameter with intense uptake at PET
(arrows). Positivity was confirmed by FNAB. Based on these finding, this lymph node was included in the GTV and received a boost of radiation
dose.
Table 2 Change of clinical stage by positron emission
tomography/computed tomography PET/CT findings.
Pre-PET
TNM
Post-PET
TNM
Tumor sites
T3N0 M0 T3N2 M0 Inguinal lymph node *
T3N0 M0 T3N2 M0 Inguinal * and external iliac lymph nodes
T3N0 M0 T3N2 M0 Inguinal *, external iliac, and perirectal
lymph nodes
T3N0 M0 T3N0 M1 Multiple liver metastases
T3N3 M0 T3N3 M1 Single liver metastasis
* confirmed by fine-needle ago-biopsy (FNAB)
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Page 4 of 7CT alone are reported in Table 4. In particular, the
mean PEToutCT volume was 10.6% of the mean CT-
GTV.
After median follow-up of 18 months (range 3 - 42
months), loco-regional control was obtained in 18/27
(66.7%) cases and disease-free and overall survival (DFS
and OS) rates were 66.7% and 77.8% respectively. Acute
and late toxicity higher than grade 2 (RTOG/EORTC)
was observed in 7/27 (25.9%) and 1/27 (3.7%) patients
respectively.
Discussion
The present study, like others reported in the litera-
ture, analyzed the potential impact of PET/CT images
on tumor staging and treatment strategy and is one
of the first reports examining quantitatively how the
GTV and the CTV for radiotherapy treatment plan-
ning may change in relation with the use of func-
tional imaging.
As a matter of fact, a number of recent literature stu-
dies tried to show that the addiction of PET and PET/
C Tm a yb ea b l et oa d du s e f u li n f o r m a t i o nf o rt h e
carcinoma of the anal canal. Most of theses studies
focused on disease staging with special regard to nodal
spread whereas relatively few of them tried to analyze
the impact of PET/CT on radiotherapy treatment plans.
Trautmann et al. reported that pre-treatment PET, in a
series of 21 patients candidates for radiotherapy and
chemotherapy, changed disease staging in 24% of cases
in relation to lymph nodal, omental, and liver metastases
[9]. Cotter et al. analyzing 41 patients affected by anal
carcinoma, observed that FDG-PET/CT detected abnor-
mal nodes in 20% of groins with normal CT appearing
leading to upstage 25% of patients [10]. Conversely 23%
of CT-positive lymph nodes were PET negative. Notably,
PET was positive in 17% of cases negative both at CT
and physical examination. More recently, Nguyen et al.
found that PET upstaged 17% of patients with unsus-
pected pelvic/inguinal nodal disease [6]. Another study
on 61 patients by Winton et al. reported a change in
tumor stage in 23% of cases as a result of PET/CT ima-
ging with 15% of upstaging and 8% of downstaging [13].
The same authors observed a change in treatment strat-
egy in 3% of patients.
Table 3 Volumes (cc) identified by CT and PET in every single case.
Patients CT-GTV PET-GTV PET/CT-GTV CT-CTV PET/CT-CTV
1 118.1 31.3 120.1 1003.8 1044.4
2 102.4 62.2 121.8 1154.4 1226.6
3 117.6 54.3 128.8 827.3 872.1
4 46.0 33.6 46.2 852.0 889.8
5 358.4 312.1 373.2 1334.0 1370.9
6 45.1 29.1 48.2 907.5 938.1
7 88.9 53.0 90.7 1266.2 1277.7
8 57.9 24.4 74.3 1077.9 1138.8
9 107.4 101.5 141.5 1038.7 1066.6
10 72.9 27.5 73.9 792.6 815.7
11 129.8 27.7 132.4 998.1 1034.2
12 31.7 9.6 32.1 685.3 711.4
13 24.5 17.8 31.3 1007.6 1046.8
14 161.3 175.8 218.2 1034.3 1146.3
15 206.1 84.5 222.1 1040.3 1121.5
16 56.8 27.8 68.9 859.3 910.9
17 82.4 21.3 82.4 812.2 847.4
18 56.7 16.9 59.9 1003.4 1040.8
19 86.6 81.7 108.2 1310.1 1380.5
20 38.4 36.1 47.9 996.5 1100.1
21 75.7 32.0 76.1 1119.1 1152.8
22 85.6 38.3 93.9 958.6 1044.2
23 42.8 11.9 43.4 1266.6 1335.6
24 27.7 12.1 28.2 854.7 919.2
25 74.0 46.9 76.5 960.8 977.1
26 13.6 13.3 17.1 734.1 760.2
27 28.0 7.1 28.1 883.8 966.1
Mean ± SD 86.5 ± 70.2 51.5 ± 63.2 95.7 ± 76.2 991.8 ± 171.2 1042.1 ± 178.1
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change in staging of 18.5% and in treatment strategy of
3.7% of cases. As reported in other studies, most
changes were found at the level of the lymph nodes,
typically in the inguinal regions even with node dia-
meter < 1.5 cm (Figure 1). In the present study, we did
not observe any downstaging of the disease possibly
related to case selection of our series. As far as the pri-
mary lesion, a case of squamous cell carcinoma showed
FDG uptake only in a part of the tumor mass detected
by CT and clinical examination. This finding could be
related to a relatively low metabolism of the tumor cells
of the PET-negative component of the lesion.
The impact of PET/CT imaging on treatment plan-
ning was analyzed only by few authors without specific
quantitative analysis of the treatment volumes. Ander-
son et al. in a series of 20 anorectal tumors found that
PTV changed, based on PET data, in 1/3 patients and
Nguyen et al. observed a significant change of the treat-
ment plan in 19% of cases because the upstage of regio-
nal lymph nodes [6,11]. More recently, Winton et al.
reported a modification of radiotherapy fields in 13% of
patients after PET/CT imaging [13].
In our series, the GTVs and the CTVs detected by CT
alone and by PET/CT images were analyzed in details
and compared. The contours outlined on PET/CT ima-
ging were substantially different from those outlined on
CT alone, more frequently for the GTV (55.6%) than for
the CTV (37.0%). This findings may be related to the
different shape of GTV detected by the two diagnostic
modalities and strongly influenced by PET uptake and
to the relatively constant shape of CTV, i.e. the potential
microscopic tumor extension, typically defined by regio-
nal anatomical landmarks on CT imaging and less influ-
enced by PET imaging. These changes were more
evident for the T3-T4 cases (80% of changes) where CT
images may be unable to clearly detect the tumor exten-
sion in relation with the close proximity of muscle
structures especially at the level of the perineum. As a
matter of fact, CT images may overestimate tumor
volume in low rectal cancer as observed by O’Neill et al.
who compared MR versus CT imaging [15].
PET/CT imaging influenced also the size of the treat-
ment volumes: more that of the GTV than that of the
CTV. In particular, the GTV defined by FDG-PET
uptake (PET-GTV) was significantly smaller than the
GTV detected by CT alone (CT-GTV) despite a number
of lymph nodes detected only by FDG-PET. This differ-
ence in size may be related to at least two different fac-
tors: on one side, CT images may include not only the
metabolically active tumor but probably also other
tumor components and possibly tissue alterations sur-
rounding the tumor itself; on the other side, PET images
may be able to highlight the metabolically active aspect
of the tumor but not the necrotic or slow growing
tumor components. The volume used for treatment pur-
poses, i.e. the PET/CT-GTV, was significantly greater
than the CT-GTV meaning that PET uptake may extend
also beyond the tumor volume visible on CT images.
This information could lead to reduce the risk of geo-
graphic miss at the periphery of the tumor. Similarly,
the PET/CT-CTV was larger than the CT-CTV in rela-
tion to the margin around the tumor extension and the
additional lymph nodes detected by PET. This difference
was evident but less pronounced than that between
PET/CT-GTV and CT-GTV because the CTV is related
to the concept of treating the microscopic disease unde-
tectable by imaging modalities.
The present study has some limitations. One is repre-
sented by the reliability of PET uptake in detecting
tumor tissue considering that data about sensitivity in
particular at the level of the regional lymph nodes is
quite high (67-100%) but the specificity cannot be ascer-
tain because of the lack of complete pathology surgical
data correlated with PET findings [13,16]. In our experi-
ence, we performed FNAB at the level of the inguinal
nodes but we did not have pathology data on the other
tumor components. Another issue is related to the
interpretation of PET uptake in terms of threshold value
to determine the real size of a positive lesion. In this
regard, we adopted the fixed threshold of 40% suggested
also by other authors and already used in a previous
study about rectal cancer, though the determination of
the most appropriate method for contouring PET
images is still under investigation [14,17-19]. However,
the very high average tumor-to-background ratio mea-
sured in our sample renders unlikely a significant
change in PET volumes using adaptive threshold algo-
rithms, which usually reach a plateau of about 40% in
this range of tumor-to-background.
Data in terms of loco-regional control and toxicity do
not substantially differ from others reported in the lit-
erature but follow-up time is too short to make any
consideration about DFS and OS [2,5,6,13].
Conclusions
The present study showed that FDG-PET/CT imaging
has a potential relevant impact in staging and target
volume delineation of the carcinoma of the anal canal.
Table 4 Volumes (cc) identified after fusion of PET and
CT images.
Volumes Mean Range Confidence Interval
PET/CT-GTV 95.7 17.1-373.2 65.5 - 125.8
PEToutCT 9.2 0.0-56.9 4.3 - 14.1
CToutPET 44.3 3.8-137.5 32.2 - 56.4
CT&PET 42.3 6.9-297.3 20.0 - 64.6
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with change of treatment intent in 3.7%. GTV and CTV
contours changed in 55.6% and 37.0% of cases respec-
tively. PET/CT-GTV and PET/CT-CTV, that were used
for clinical purposes, were significantly greater than CT-
GTV and CT-CTV. These variations in treatment
volumes may become very relevant when using highly
conformal techniques like intensity modulated radiation
therapy or particle therapy.
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